Jian Chen1,2, Fengcai Du3, Baohong Hu1, Cheng Chi1, Hongjin Chu2, Lixin Jiang4, Peng Li1, Zhaohua Gong5. 1. Department of Oncology, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. China. 2. The Central Laboratory, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. China. 3. The First Clinical College of DaLian Medical University, Dalian, P.R. China. 4. Department of Gastrointestinal Surgery, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. China. 5. Department of Oncology, the Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, P.R. China gongzhoahuayt@163.com.
Abstract
BACKGROUND/AIM: Bevacizumab combined with standard chemotherapeutics has become a choice of treatment for several kinds of cancers. Hypertension, third-degree albuminuria, thrombosis and cardiotoxicity are the reported side-effects of bevacizumab. Among them, cardiotoxicity is a most severe, but rare outcome. We report a case of a 62-year-old female with colorectal carcinoma who was given bevacizumab-containing chemotherapy for more than 20 months and achieved a stable disease during the entire course of treatment. Thereafter, she developed cardiotoxicity including grade 3 hypertension, tricuspid regurgitation, pulmonary hypertension, left ventricular diastolic dysfunction and pericardial effusion, and was discontinued from the regimen with bevacizumab. CONCLUSION: Although clinically-effective, the severe cardiotoxicity of bevacizumab developed after over 20 courses of treatment prompted us to look for optimal chemotherapy prescription in order to achieve a better clinical outcome. Copyright
BACKGROUND/AIM: Bevacizumab combined with standard chemotherapeutics has become a choice of treatment for several kinds of cancers. Hypertension, third-degree albuminuria, thrombosis and cardiotoxicity are the reported side-effects of bevacizumab. Among them, cardiotoxicity is a most severe, but rare outcome. We report a case of a 62-year-old female with colorectal carcinoma who was given bevacizumab-containing chemotherapy for more than 20 months and achieved a stable disease during the entire course of treatment. Thereafter, she developed cardiotoxicity including grade 3 hypertension, tricuspid regurgitation, pulmonary hypertension, left ventricular diastolic dysfunction and pericardial effusion, and was discontinued from the regimen with bevacizumab. CONCLUSION: Although clinically-effective, the severe cardiotoxicity of bevacizumab developed after over 20 courses of treatment prompted us to look for optimal chemotherapy prescription in order to achieve a better clinical outcome. Copyright
Authors: Mark E Orcholski; Ke Yuan; Charlotte Rajasingh; Halley Tsai; Elya A Shamskhou; Navneet K Dhillon; Norbert F Voelkel; Roham T Zamanian; Vinicio A de Jesus Perez Journal: Am J Physiol Lung Cell Mol Physiol Date: 2018-02-08 Impact factor: 5.464